Abstract
Anaplastic large cell lymphoma (ALCL) accounts for 10–15% of childhood non-Hodgkin lymphoma cases; it is generally chemo-sensitive and is one of the most curable pediatric cancers. We report here a case of pediatric ALCL complicated with acute liver failure due to the aggravation of pre-existing biliary hepatopathy by lymphoma-associated hemophagocytic lymphohistiocytosis (HLH). Although the initial treatment response against ALCL was very good, poor and irreversible liver function due to biliary cirrhosis worsening by lymphoma-associated HLH prevented the patient from receiving further consolidation chemotherapies. To make matters worse, his condition was accompanied with intrahepatic fungal pseudoaneurysm and invasive fungal infection. Thus, we decided to perform an urgent living-donor liver transplantation from his father to correct the patient’s liver function and make it possible to proceed with further ALCL therapy. After the living-donor liver transplantation, the patient successfully received consolidation therapy with brentuximab vedotin. To our knowledge, this may be an early reported case of a pediatric patient undergoing liver transplantation during treatment for ALCL. In most patients with HLH-associated ALCL, liver function improves when ALCL is controlled. However, acute liver failure is occasionally observed in HLH cases with pre-existing liver dysfunction. In such cases, liver transplantation should be considered to correct liver dysfunctions if the disease control of HLH is satisfactory.
Similar content being viewed by others
References
Alessandri AJ, Pritchard SL, Schultz KR, Massing BG. A population-based study of pediatric anaplastic large cell lymphoma. Cancer. 2002;94:1830–5.
Amin HM, Lai R. Pathobiology of ALK + anaplastic large-cell lymphoma. Blood. 2007;110:2259–67.
Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56:1071–7.
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5:e450–61.
Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86:58–65.
Ryu JM, Kim KM, Oh SH, Koh KN, Im HJ, Park CJ, et al. Differential clinical characteristics of acute liver failure caused by hemophagocytic lymphohistiocytosis in children. Pediatr Int. 2013;55:748–52.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–16.
Wang H, Xiong L, Tang W, Zhou Y, Li F. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget. 2017;8:59977–85.
Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170:539–49.
Pasqualini C, Minard-Colin V, Saada V, Lamant L, Delsol G, Patte C, et al. Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children. Br J Haematol. 2014;165:117–25.
Bergsten E, Horne A, Arico M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130:2728–38.
Amir AZ, Ling SC, Naqvi A, Weitzman S, Fecteau A, Grant D, et al. Liver transplantation for children with acute liver failure associated with secondary hemophagocytic lymphohistiocytosis. Liver Transpl. 2016;22:1245–53.
Ayvazoğlu Soy EH, Alam H, Olcay L, Barış Z, Yıldırım S, Torgay A, et al. Liver transplant in a patient with hemophagocytic lymphohistiocytosis. Exp Clin Transplant. 2019;17:226–9.
Cuenca AG, Kim HB, Vakili K. Pediatric liver transplantation. Semin Pediatr Surg. 2017;26:217–23.
Acknowledgements
We would like to thank Kaoru Yoshida of the Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development for performing the RT-PCR and direct sequencing of NPM-ALK.
Author information
Authors and Affiliations
Contributions
KS collected data and provided medical care for this case, and wrote the manuscript supported by MK and DT. TO, SY, SS, MK, DT, SS, OM, SN, MK, and KM provided medical care for this case. TD and NK performed flow-cytometric analysis. NN, TY, and RI performed pathological diagnostic procedures. All authors commented on the manuscript and contributed to the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
12185_2020_2949_MOESM1_ESM.pdf
Supplementary material 1 (PDF 223 kb) Figure 1. Image findings at 12 months post-liver transplantation and at 8 months after cessation of chemotherapy. A, B Abdominal computerized tomography (CT) shows no hepatosplenomegaly nor lymphadenopathy; C, D positron emission tomography with CT (PET-CT) reveals no high radiotracer accumulation at lymph nodes.
About this article
Cite this article
Sakamoto, K., Osumi, T., Yoshimura, S. et al. Living-donor liver transplantation providing an adequate chemotherapy for a pediatric patient with anaplastic large cell lymphoma complicated with liver failure due to the aggravation of biliary hepatopathy by secondary hemophagocytic lymphohistiocytosis. Int J Hematol 112, 900–905 (2020). https://doi.org/10.1007/s12185-020-02949-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-020-02949-z